Iris Gorfinkel is a General Practitioner, and Founder and Principal Investigator at PrimeHealth Clinical Research in Toronto, Ontario.
On July 10, 2018 Health Canada issued a recall of several products containing the blood pressure lowering drug, valsartan. This came in response to a disclosure from its Chinese manufacturer that the drug had been contaminated with a known carcinogen. A massive effort to contact patients to stop the affected drug lots, and to replace it with an alternative, ensued. Few clinicians had been even remotely aware that ...continue reading →
Many food labels in a supermarket constitute information-overload for consumers. However, I have yet to see labels that appraise us about the utilization of GE materials for production of the product. To me and many others, this contravenes our fundamental “right to know” ...continue reading →
If you look at an old map of Canadian healthcare policy, just near Privatization Island is a big warning: “Here be dragons.” So it proved for Alberta Health Services recently when a seemingly innocuous decision -- to swap the tender for laboratory services from a United States-based transnational corporation to an Australian one -- provoked a furore fueled by discontent.
Part of the problem is that ‘privatization’ has two meanings. One refers to an increase in the private funding of healthcare. In the Canadian context that is unequivocally bad. It breaks the compact between Canadians that they are all in the same boat in terms of access to healthcare and strikes at one of the key differences between the U.S. and Canada. On one side of the border, people can sleep easy knowing they are protected against the costs of healthcare if something goes wrong for them or their family. On the southern side, the spectre of bankruptcy or no care looms, even in the post-Obamacare world.
But Alberta’s controversy over lab contracts is about a different sort of privatization. It is about who delivers care within the publically funded system. ...continue reading →